Manufacturing method of targeted magnetic nanometer probe for early diagnosis of atherosclerosis vulnerable plaques

Abstract

The invention relates to a manufacturing method of a targeted magnetic nanometer probe for early diagnosis of atherosclerosis vulnerable plaques, which is used for carrying out experiment research for the early warning of vulnerable plaques at an early stage and providing experimental data support for development and popularization of an innovation-type diagnostic reagent, so that not only can unstable plaques be effectively found and pre-warned at the early stage, but also the curative effect of the novel anti-atherosclerosis drug can be evaluated. The manufacturing method disclosed by the invention comprises the following steps of: using Fe3O4 nanometer particles PEI (Polyethyleneimine)-Fe3O4-NP (Nonyl Phenol) of PEI as carriers; and connecting profilin-1 antibodies on the surfaces of the carriers by a chemical synthesis method to form the magnetic nanometer probe PF(Profilin)1-PEI-Fe3O4-NP of the targeted profiling-1 protein.

Description

1. Technical field: [0001] The invention relates to a molecular probe in a medical diagnostic reagent, in particular to a preparation method of a targeting magnetic nanometer probe for early diagnosis of vulnerable plaques of atherosclerosis. 2. Background technology: [0002] At present, acute cardiovascular events, mainly acute myocardial infarction and sudden cardiac death, have become the number one killer of human health. According to statistics, about 20 million people die of acute cardiovascular events in the world every year. In my country, the situation is also not optimistic. More than 700,000 people die of acute myocardial infarction and sudden cardiac death every year, which has become one of the most important diseases that seriously threaten the health of Chinese residents. The majority of acute myocardial infarction and sudden cardiac death are caused by rupture of vulnerable plaque. Vulnerable plaques refer to plaques that are unstable and prone to thrombos...

AI Technical Summary

Problems solved by technology

However, the probes currently used for research mainly have the following two shortcomings. First, the target of the probes is almost always expressed in the middle and late stages of vulnerable plaque formation, but not in the early stages of the disease. significant changes, making it difficult to achieve early diagnosis of vulnerable plaques using these targeted probes

Second, in many studies, the choice of probe carrier is the surface untreated Fe 3 o 4 Nanoparticles, which have poor stability in the body, are easy to accumulate, and have a short residence time and short observation time; the other is that the small molecule Gd reagent has strong nephrotoxicity, especially for patients with renal insufficiency. The residence time in the body is too short, and its clinical injection dose is relatively large

Images